

# Author Index Volume 55 January-June 1997

- Aiying, W., 15  
Alexander, N.J., 261  
Alihonou, E., 97  
Alvarado, G., 359  
Alvarez, F., 81, 225  
Anant, M.P., 73  
Archer, D.F., 139
- Bahamondes, L., 307  
Barbosa, I., 175  
Bardin, C.-W., 35  
Barditch-Crovo, 261  
Barraza-Vasquez, A., 311  
Bartenstein, P., 87  
Basnayake, S., 225  
Bassol, S., 311, 359  
Bastianelli, C., 295  
Belsey, E.M., 57  
Belsey, M., 323  
Benegiano, G., 295  
Bianchi, P., 295  
Bihareus, P., 81  
Bloemenkamp, K.W.M., 189  
Bock, J.E., 287  
Botterman, P., 87  
Brache, V., 81, 225  
Brinton, L.A., 197
- Canto-de-Cetina, T., 359  
Campodonico, I., 73  
Capochichi, V., 97  
Carbonell, J.L.L., 165  
Carr, B.A., 267  
Carre, N., 97  
Chaturachinda, K., 205, 283, 351  
Coates, R.J., 197  
Coffin, C.J., 323  
Coutinho, E.M., 175  
Cowchock, S., 53  
Crook, D., on behalf of the UK Study Group, 219  
Croxatto, H.B., 225
- D'Antona, D., 239  
D'Aurea Abranches, A., 175  
Daling, J.R., 197  
Dao, B., 35  
Darney, P., 81  
de Barros Leal, W., 175  
de Souza, R.N., 175  
De Palma, P., 239  
De Leo, V., 239
- del Carmen Cravioto, M., 359  
DelConte, A., 139  
Diaz, J., 307  
Diaz, S., 73, 81, 225  
Díaz, S., 225  
Diez, M.J., 47  
Du, M.-K., 225  
Dunmire, E.N., 115, 209  
Düsterberg, B., 131
- el din Abdalla, K., 73  
El-Sawi, M., 7  
Endrikat, J., 131
- Farahmand, S., 19  
Felix, J.C., 19  
Fernández, C., 165  
Fernandez, N., 47  
Fletcher, V., 327, 337  
Foldes, R., 169  
Fuziwara, J.L., 359
- Gammon, M.D., 197  
Ganguli, N.K., 315  
Garcia, J.J., 47  
Garza-Flores, J., 359  
Gatto, M., 175  
Gbolade, B.A., 319  
Ghosh, D., 103  
Goldzieher, J.W., 233  
Grubb, G.S., 245  
Gupta, I., 315
- Hamzeh, F., 261  
Hannaford, P.C., 145  
Harman, S.M., 23  
Hartard, M., 87  
Hellberg, D., 355  
Helmerhorst, F.M., 189  
Hemminki, E., 153  
Hight-Laukaran, 327, 337  
Hippolito, S.B., 175  
Holma, P., 73
- Intaraprasert, S., 205, 283, 351
- Jackanicz, T., 225  
Jeschke, D., 87  
Jinsong, Q., 369  
Juárez-Perez, M.A., 245
- Katz, D.F., 115, 209  
Kay, C.R., 145  
Kennedy, K.I., 347  
Khamis, Y., 7  
Khan, H.T.A., 91  
Khan-Dawood, F.S., 233  
Kiode, S.S., 35  
Kiriwat, O., 73  
Klaisle, C., 81  
Knudsen, L.B., 301  
Koctasawang, S., 73, 81, 225  
Kosunen, E., 153  
Krüger Kjaer, S., 287
- Labbok, M.H., 323, 327, 337  
Lacarra, M., 81, 225  
LaGuardia, K., 81  
Lähteenmäki, P., 81  
Lanzetta, D., 239  
Lasa, L.I., 53  
Lasley, B.L., 103  
Lavín, P., 307  
Leal, C., 175  
Ledger, W.J., 23  
Leonard, R.J., 23  
Levine, A.B., 53  
Lewis, M.A., 189  
Li, X.-J., 35  
Lynam, P.F., 249
- Maheux, R., 139  
Malone, E., 197  
Maradiegue, E., 307  
Mårdh, P.-A., 355  
Marr, J., 145  
Marzouk, S., 7  
McCarthy, T., 225  
McPherson, J., 261  
Medda, E., 295  
Mehanna, M.T.R., 7  
Mezrich, R.S., 169  
Miranda, P., 225  
Mishell, Jr., D.R., 81, 225  
Monteiro, I., 307  
Morais, K., 175  
Moreno, J.E., 233  
Morgante, G., 239  
Müller, U., 131
- Nair, K.M., 373  
Nash, H., 81  
Nava, M.P., 311

- Navarrete, T., 359  
Nayak, N.R., 103  
Neto, J.S.P., 175  
Nilsson, S., 355
- Ojeda, G., 307  
Oropeza, G., 359  
Ory, H., 267  
O'Brien, F.B., 139
- Painter, R., 145  
Palma, Y., 359  
Pasquale, S.A., 169  
Pavez, M., 73, 81  
Perada, P., 47  
Pérez-Palacios, G., 359  
Peterson, A.E., 327, 337  
Petta, C., 307  
Phuapradit, W., 205  
Pinol, A.P.Y., 57  
Piya-Anant, M., 81  
Poll, P., 287  
Ponce de León, R., 245  
Pradhan, M., 315  
Primiero, F.M., 295
- Qiming, X., 369
- Raghubanshi, R.S., 23  
Ramadan, M., 7  
Ranta, S., 81  
Ravinder, P., 373  
Recio, R., 311  
Rosendaal, F.R., 189
- Ruminjo, J.K., 249  
Russer, T.J., 169
- Santos-Yung, R., 359  
Saxena, B.B., 23  
Sayed, E.H., 225  
Schoenberg, J.B., 197  
Schwaiger, M., 87  
Schwingl, P.J., 125  
Sengupta, J., 103  
Shaaban, M., 225  
Shaobo, X., 369  
Shatrugna, V., 373  
Shelton, J., 125  
Short, R.V., 347  
Shoubnikova, M., 355  
Sierra, M., 47  
Sihvo, S., 153  
Singh, M., 23  
Sivakumar, B., 373  
Sivin, I., 73, 81, 225  
Skjeldstad, F.E., 11  
Spinola, P., 175  
Stanczyk, F.Z., 273  
Stern, J., 73, 81, 225  
Stratton, P., 261  
Svare, E.I., 287
- Taneepanichskul, S., 205, 283, 351  
Teng, C.S., 41, 183  
Terán, T., 47  
Thonneau, P., 97  
Tomaz, G., 175
- Toppozada, M.K., 7  
Trapnell, C.B., 261  
Tully, M.R., 347
- UK Study Group, 219
- Valencia, J., 359  
Vanage, G., 35  
Vandenbroucke, J.P., 189  
Van Look, P.F.A., 327, 337  
Varela, L., 165  
Velazco, A., 165  
Vessey, M.P., 145  
Viegas, O., 73  
Viegas, O.A.C., 81  
Villegas-Salas, E., 245  
von Hertzen, H., 327, 337
- Wan, L., 73, 81  
Wei, Z., 15  
Weiss, N.S., 189  
Wiebe, E.R., 67, 159  
Wielandt, H.,  
Witter, F., 261  
Wu, S.-C., 225
- Xiao, B., 225
- Yang, Z., 15  
Yazlle, M.E., 175  
Yibin, S., 369  
Yimin, C., 15  
Ying, W., 369
- Zhimin, L., 15

# Subject Index Volume 55 January-June, 1997

- Abortion seekers, contraceptive practices, 15
- Abortions related to adverse media coverage, 11
- Acceptability, Lactational Amenorrhea Method, 337
- Adverse media coverage, effect on induced abortions, 11
- Amoxicillin-ethinylestradiol, pharmacokinetic interaction (rabbit), 47
- Anaphylactoid reaction, post Norplant implants insertion, 319
- Antifertility effect, LHRH antagonist (male rats), 369
- Anti-implantation activity, RU 486 (monkey), 103
- Antiprogestins  $\pm$  anandiol, pregnancy termination (rat), 35
- Bacterial vaginosis, contraceptive use, 355
- Biodegradable implants, clinical study, 23
- Birth control experience in Denmark, 301
- Bone mineral density, effect of exercise and OCs, 87
- Breast cancer risk and OCs, 197
- Breastfeeding, Lactational Amenorrhea Method, 327, 337
- Breastfeeding definitions, 323
- Buserelin, effect on male infants, 311
- Carbohydrate metabolism,
  - effect of estradiol valerate + norethisterone enantate, 295
  - effect of ethinylestradiol + norethisterone, 295
- Cervical mucus, permeation of nonoxynol-9, 115
- Citrulline, L-, level in copper IUD users, 315
- Clinical guidance, Lactational Amenorrhea Method, 327
- Clinical trial,
  - estradiol enanthate + dihydroxyprogesterone acetophenide, 175
  - ethinylestradiol + gestodene, 131
  - Norplant implants, 359
  - Norplant-II implants, 359
- Clinically important bleeding patterns, 57
- Continuation of contraceptive methods, determinants, 97
- Contraceptive continuation in Benin, 97
- Contraceptive practices, women requesting pregnancy termination, 15
- Contraceptive use,
  - determinants, 287
  - bacterial vaginosis, 355
- Contraceptive use in Bangladesh, 91
- Copper IUD users, nitrites and L-citrulline levels, 315
- Copper T 380A IUD, 225
- Cortisol levels, effect of Norplant implants, 7
- CUE<sup>®</sup> method, natural family planning, 233
- CuT380A IUD, interaction between magnetic resonance imaging, 169
- Definitions of breastfeeding, 323
- Determinants for contraceptive use, 287
- Emergency contraception, knowledge and use, 153
- Endocrine function, effect of ethinyl estradiol + desogestrel, 219
- Endometrial glandular proliferation and hormone receptor status, 19
- Estradiol cypionate + medroxyprogesterone acetate, 307
- Estradiol enanthate + dihydroxyprogesterone acetophenide, clinical trial, 175
- Estradiol valerate + norethisterone enanthate, 295
- Estrogen receptor content and endometrial glandular proliferation, 19
- Ethinyl estradiol and amoxicillin, pharmacokinetic interaction (rabbit), 47
- Ethinyl estradiol + desogestrel, 219
- Ethinyl estradiol + gestodene, clinical trial, 131
- Ethinyl estradiol + levonorgestrel, efficacy and safety study, 139
- Ethinyl estradiol + norethisterone, 295
- Ethinyl estradiol metabolism, influence of gestodene and desogestrel, 273
- Exercise and OC use, effect on bone mineral density, 87
- Family planning, Lactational Amenorrhea Method, 327, 337
- Female sterilization,
  - laparoscopy, 283
  - minilaparotomy, 249, 351
- Fertility, following estradiol cypionate + medroxyprogesterone acetate, 307
- Gemeprost + RU 486, pregnancy termination, 1
- Gestodene, pharmacokinetics, 273
- Gossypol, effect on spermatogenic cells (rat), LLL
- Hierarchical model of contraceptive use, 91
- HIV-1 infected women, use of Norplant implants, 205
- Hormonal emergency contraception, 153

- Hormone replacement therapy, transdermal  
estradiol + progestogens, 239
- Implant contraceptive,  
levonorgestrel, 7, 73, 81, 205, 359  
norethindrone-cholesterol, 23
- Injectable contraceptive,  
estradiol cypionate + medroxyprogesterone  
acetate, 307  
estradiol enanthate + dihydroprogesterone  
acetophenide, 175  
estradiol valerate + norethisterone enantate, 295
- Intrauterine device (IUD), copper T 380A, 169, 225
- L-citrulline level, copper IUD users, 315
- Lactating women,  
use of copper T 380A IUD, 225  
use of progesterone vaginal ring, 225
- Lactation, use of progestin-only contraceptive  
methods, 347
- Lactational Amenorrhea Method, 327, 337
- Laparoscopic female sterilization, 283
- Levonorgestrel concentrations, levonorgestrel rod  
implants, 81
- Levonorgestrel rod implants,  
clinical performance, 73  
levonorgestrel concentrations, 81
- LHRH antagonist, antifertility effect (male rats), 369
- Lipid metabolism,  
effect of estradiol valerate + norethisterone  
enantate, 295  
effect of ethinyl estradiol + desogestrel, 219  
effect of ethinyl estradiol + norethisterone, 295
- Liver disease and OC use, 145
- Magnetic resonance imaging, interaction with  
CuT380A, 169
- Male infants, effect of buserelin, 311
- Medical abortions vs. surgical abortions, 67
- Menstrual bleeding patterns, untreated women, 57
- Methotrexate + misoprostol,  
comparison of various protocols, 159  
pregnancy terminations, 67
- Mifepristone (RU 486)
- Minilaparotomy, female sterilization, 249, 351
- Misoprostol, pregnancy termination, 165
- Myocardial infarction, OC users, 125
- Natural family planning,  
CUE® method, 233  
Ovulation Detection Method, 233  
Lactational Amenorrhea Method, 327, 337
- NET (norethindrone)
- NET:cholesterol pellets, Anuelle®, 23
- Nitrites level, copper IUD users, 315
- Nonoxynol-9,  
effect on sperm kinematics, PPP  
method for collection and recovery when  
vaginally administered, 261  
permeation into cervical mucus, 115
- Norethindrone-cholesterol implants, clinical study,  
23
- Norethisterone enanthate,  
pharmacokinetics, 373  
pharmacokinetics (rabbit, monkey), 373
- Norgestimate, pharmacokinetics, 273
- Norplant® implants, 7, 73, 205, 359
- Norplant® implants insertion, anaphylactoid  
reaction, 319
- Norplant®-II implants, 359
- OC (oral contraceptive)
- OC use and exercise, effect on bone mineral  
density, 87
- OC use and liver disease, 145
- OCs and breast cancer risk, 197
- OCs and vascular disease, 267
- OCs and venous thromboembolism, 189
- OCs risk and recency of market introduction, 191
- Oral contraceptive (OC),  
ethinyl estradiol + desogestrel, 219  
ethinyl estradiol + gestodene, 131  
ethinyl estradiol + levonorgestrel, 139  
ethinyl estradiol + norethisterone, 295  
ethinyl estradiol + norgestrel, 245
- Ovulation Detection Method, natural family  
planning, 233
- Perimenopausal women, transdermal estradiol +  
progestogens, 239
- Pharmacokinetic interaction, ethinyl estradiol-  
amoxicillin (rabbit), 47
- Pharmacokinetics,  
gestodene, 273  
norgestimate, 273  
oral norethisterone enanthate, 373  
oral norethisterone enanthate (rabbit, monkey),  
373
- Pituitary-adrenal function, effect of Norplant  
implants, 7
- Pregnancy termination,  
antiprogestins ± anordiol (rat), 35  
methotrexate + misoprostol, 67, 159  
misoprostol, 165  
RU 486 + gemeprost, 1
- Prethrombotic state, evaluation, 53
- Progestin-only contraceptives, use during lactation,  
347
- Progesterone-releasing vaginal ring, 225

Quantitation of vaginally administered nonoxynol-9, 261

Reactive nitrogen intermediates, copper IUD users, 315

Recency of market introduction, risk of OCs, 191

Return of fertility, following estradiol cypionate + medroxyprogesterone acetate, 307

RU 486, anti-implantation activity (monkey), 103

RU 486 + gemeprost, pregnancy termination, 1

Second generation OCs, 125

Side effects of OC use, effect of vitamin B<sub>6</sub>, 245

Sperm kinematics, effect of nonoxynol-9, 209

Spermatogenic cells, effect of gossypol (rat), 183

Surgical abortions vs. medical abortions, 67

Third generation OCs, 11, 125

Transdermal estradiol + progestogens, perimenopausal women, 239

Vaginal ring, progesterone-releasing, 225

Vascular disease and OCs, 267

Venous thromboembolic disease, OC users, 125

Venous thromboembolism and OC use, 189

Vitamin B<sub>6</sub>, effect on side effects of OC use, 245